标题
New antibody approaches to lymphoma therapy
作者
关键词
Bispecific T-cell engager, Cd-20, Pd-1, Cd-22, Monoclonal, Lymphoma, Antibodies
出版物
Journal of Hematology & Oncology
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-09-08
DOI
10.1186/s13045-014-0058-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
- (2015) Jonathan Feld et al. Oncotarget
- Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma
- (2014) G. Franco et al. BLOOD
- Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations
- (2014) Geraldine O'Sullivan Coyne et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- (2014) Michinori Ogura et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial
- (2013) C. Binder et al. ANNALS OF HEMATOLOGY
- Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma
- (2013) M. J. Matasar et al. BLOOD
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
- (2013) J. Radford et al. BLOOD
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
- (2013) J. Golay et al. BLOOD
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
- (2013) J. H. Myklebust et al. BLOOD
- A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma
- (2013) Bertrand Coiffier et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
- (2013) Michelle Fanale et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701
- (2013) Barbara W. Grant et al. CANCER
- Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)
- (2013) Tait Shanafelt et al. CANCER
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2013) J. R. Brown et al. HAEMATOLOGICA
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Franck Andre Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
- (2013) S. Rafiq et al. JOURNAL OF IMMUNOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells
- (2013) S Munir et al. LEUKEMIA
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others
- (2013) Hideaki Kobayashi et al. Cancer Medicine
- Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study
- (2012) M. S. Czuczman et al. BLOOD
- Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
- (2012) Myron S. Czuczman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
- (2012) Andres Forero-Torres et al. CLINICAL CANCER RESEARCH
- Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
- (2012) Takashi Ishida et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
- (2012) Andres Forero-Torres et al. LEUKEMIA & LYMPHOMA
- Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
- (2012) John C. Byrd et al. LEUKEMIA & LYMPHOMA
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
- (2011) I. N. M. Micallef et al. BLOOD
- Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
- (2011) W. G. Wierda et al. BLOOD
- Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
- (2011) W. G. Wierda et al. BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma
- (2011) T. S. Lewis et al. CLINICAL CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results
- (2011) Joshua Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment
- (2011) Donatella Aldinucci et al. LEUKEMIA & LYMPHOMA
- Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia
- (2011) Giuseppe Gritti et al. LEUKEMIA & LYMPHOMA
- CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients
- (2011) Y.H. Kim et al. MELANOMA RESEARCH
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- (2010) Kensei Tobinai et al. CANCER SCIENCE
- Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma
- (2010) G. O. Negrea et al. HAEMATOLOGICA
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
- (2010) Kazuhito Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
- (2010) R. Herbst et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
- CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
- (2010) Karin Rydström et al. LEUKEMIA & LYMPHOMA
- CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
- (2010) Stephen A. Beers et al. SEMINARS IN HEMATOLOGY
- Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
- (2010) Capucine Daridon et al. ARTHRITIS RESEARCH & THERAPY
- Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
- (2009) M. Gobert et al. CANCER RESEARCH
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
- (2009) Susumu Uchiyama et al. CANCER SCIENCE
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
- (2009) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
- (2009) A Österborg et al. LEUKEMIA
- CD19: a promising B cell target for rheumatoid arthritis
- (2009) Thomas F. Tedder Nature Reviews Rheumatology
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
- (2008) D. M. Goldenberg et al. BLOOD
- The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
- (2008) M. Luqman et al. BLOOD
- Durable complete responses from therapy with combined epratuzumab and rituximab
- (2008) John P. Leonard et al. CANCER
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer
- (2008) Yoshiki Mizukami et al. INTERNATIONAL JOURNAL OF CANCER
- PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients
- (2008) T Kozako et al. LEUKEMIA
- Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
- (2008) Bruce D. Cheson et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia
- (2008) S. Demko et al. ONCOLOGIST
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- Germinal center structure and function: Lessons from CD19
- (2008) Robert H. Carter et al. SEMINARS IN IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now